Invasive fungal infections are a major cause of health care–associated morbidity and mortality in the ICU. In particular, Candida spp. are among one of the leading causes of bloodstream infections and sepsis. Advances in antifungal therapy in the last decade have led to many more options in the treatment of fungal infections, yet increasing resistance and clinical failures are common, especially in the management of invasive candidiasis in the ICU. Prompt diagnosis of these infections and appropriate antifungal treatment are imperative for improving survival. Although reliable antifungal susceptibility testing is available to aid in the therapy of fungal infections, testing is not always recommended. This review addresses the epidemiology of Candida infections in the ICU, antifungal resistance, therapy, and the usefulness of antifungal susceptibility testing in the ICU setting.
PfallerMADiekemaDJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20:133–163.
2.
PfallerMADiekemaDJGibbsDL. Results from the ARTEMIS DISK Global Anitfungal Surveillance Study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol. 2007;45:1735–1745.
3.
PlayfordEGEggimannPCalandraT. Antifungals in the ICU. Curr Opin Infect Dis. 2008;21:610–619.
4.
McNeilMMNashSLHajjehRA. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis. 2001;33:641–647.
5.
MartinGSManninoDMEatonSMossM. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546–1554.
6.
MeanMMarchettiOCalandraT. Bench-to-bedside review: Candida infections in the intensive care unit. Crit Care. 2008;12:204–212.
7.
BouzaEMunozP. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents. 2008;32(suppl 2):S87–S91.
8.
PappasPGKauffmanCAAndesD. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–535.
9.
HollenbachE. Invasive candidiasis in the ICU: evidence based and on the edge of evidence. Mycoses. 2008;51(suppl 2):25–45.
10.
WisplinghoffHBischoffTTallenSM. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–317.
11.
GueryBPArendrupMCAuzingerG. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. epidemiology and diagnosis. Intensive Care Med. 2009;35:55–62.
12.
PfallerMABoykenLHollisRJ. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol. 2008;46:150–156.
13.
ShorrAFLasarusDRShernerJH. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit Care Med. 2007;35:1077–1083.
14.
TrickWEFridkinSKEdwardsJR. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999: National Nosocomial Infections Surveillance System Hospitals. Clin Infect Dis. 2002;35:627–630.
15.
FleckRHofH. Breakpoints for posaconazole susceptibility testing: background and discussion about the need of establishing values. Mycoses. 2008;51(suppl 2):1–4.
16.
ArendrupMCGarcia-EffronGBuzinaW. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob Agents Chemother. 2009;53:1185–1193.
17.
Garcia-EffronGKontoyiannisDPLewisREPerlinDS. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother. 2008;52:4181–4183.
18.
BaixenchMTAounNDesno-OllivierM. Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother. 2007;59:1076–1083.
19.
Garnacho-MonteroJDiaz-MartinACayuela-DominguezA. Management of invasive Candida infections in non-neutropenic critically ill patients: from prophylaxis to early therapy. Int J Antimicrob Agents. 2008;32(suppl 2):S137–S141.
20.
LabelleAJMicekSTRoubinianNKollefMH. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med. 2008;36:2967–2972.
21.
MorrellMFraserVJKollefMH. Delaying empiric treatment of Candida bloodstream infections until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49:3640–3645.
22.
GareyKWRegeMPaiMP. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43:25–31.
23.
LeonCRuiz-SantanaSSaavedraP. Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med. 2009;37:1624–1633.
24.
Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Third Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2008. CLSI document M27-A3.
25.
PfallerMADiekemaDJSheehanDJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev. 2006;19:435–447.
26.
PosteraroBMartucciRLa SordaM. Reliability of the Vitek 2 yeast susceptibility test for detection of in vitro resistance to fluconazole and voriconazole in clinical isolates of Candida albicans and Candida glabrata. J Clin Microbiol. 2009;47:1927–1930.
27.
ForrestG. Role of antifungal susceptibility testing in patient management. Curr Opin Infect Dis. 2006;19:538–543.
28.
CollinsCDEschenauerGASaloSLNewtonDW. To test of not to test: a cost minimization analysis of susceptibility testing for patients with documented Candida glabrata fungemias. J Clin Microbiol. 2007;45:1884–1888.
